This is due to an overproduction of fibroblast growth factor 23 (FGF23) from benign mesenchymal tumors, leading to disruptions in renal metabolism, lowered vitamin D3 concentration, and decreased phosphate reabsorption [[2], [3], [4]]. Here, FGF23 is linked to mesenchymal cell neoplasm.